vs
Fiverr International Ltd.（FVRR）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Fiverr International Ltd.的季度营收约是Orthofix Medical Inc.的1.3倍（$287.8M vs $219.9M），Fiverr International Ltd.净利率更高（1.9% vs -1.0%，领先2.9%），Fiverr International Ltd.自由现金流更多（$52.1M vs $16.8M），过去两年Fiverr International Ltd.的营收复合增速更高（29.5% vs 8.0%）
Fiverr International Ltd.运营全球在线自由职业服务平台，连接160余个国家的企业客户与独立创作者，提供数字营销、平面设计、编程、文案撰写、视频剪辑等多领域专业服务，满足各类客户灵活的按需用工需求。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FVRR vs OFIX — 直观对比
营收规模更大
FVRR
是对方的1.3倍
$219.9M
净利率更高
FVRR
高出2.9%
-1.0%
自由现金流更多
FVRR
多$35.2M
$16.8M
两年增速更快
FVRR
近两年复合增速
8.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $287.8M | $219.9M |
| 净利润 | $5.4M | $-2.2M |
| 毛利率 | 82.5% | 71.1% |
| 营业利润率 | -3.5% | 0.2% |
| 净利率 | 1.9% | -1.0% |
| 营收同比 | — | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FVRROFIX
| Q4 25 | — | $219.9M | ||
| Q3 25 | $287.8M | $205.6M | ||
| Q2 25 | $188.2M | $203.1M | ||
| Q1 25 | $93.5M | $193.6M | ||
| Q4 24 | — | $215.7M | ||
| Q3 24 | $269.9M | $196.6M | ||
| Q2 24 | $177.3M | $198.6M | ||
| Q1 24 | $88.0M | $188.6M |
净利润FVRROFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $5.4M | $-22.8M | ||
| Q2 25 | $4.1M | $-14.1M | ||
| Q1 25 | $788.0K | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $-1.0M | $-27.4M | ||
| Q2 24 | $-4.0M | $-33.4M | ||
| Q1 24 | $-4.3M | $-36.0M |
毛利率FVRROFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | 82.5% | 72.2% | ||
| Q2 25 | 83.3% | 68.7% | ||
| Q1 25 | 83.5% | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | 82.8% | 68.7% | ||
| Q2 24 | 82.4% | 67.8% | ||
| Q1 24 | 82.2% | 67.5% |
营业利润率FVRROFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | -3.5% | -8.3% | ||
| Q2 25 | -3.4% | -7.9% | ||
| Q1 25 | -4.4% | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | -5.0% | -9.6% | ||
| Q2 24 | -6.3% | -12.5% | ||
| Q1 24 | -8.1% | -15.6% |
净利率FVRROFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 1.9% | -11.1% | ||
| Q2 25 | 2.2% | -6.9% | ||
| Q1 25 | 0.8% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | -0.4% | -13.9% | ||
| Q2 24 | -2.3% | -16.8% | ||
| Q1 24 | -4.9% | -19.1% |
每股收益（稀释后）FVRROFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.57 | ||
| Q2 25 | — | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.71 | ||
| Q2 24 | — | $-0.88 | ||
| Q1 24 | — | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $133.5M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $362.6M | $450.0M |
| 总资产 | $1.1B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FVRROFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | $133.5M | $62.9M | ||
| Q2 25 | $578.4M | $65.6M | ||
| Q1 25 | $133.5M | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | $183.7M | $30.1M | ||
| Q2 24 | $183.7M | $26.4M | ||
| Q1 24 | $183.7M | $27.0M |
总债务FVRROFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益FVRROFIX
| Q4 25 | — | $450.0M | ||
| Q3 25 | $362.6M | $442.5M | ||
| Q2 25 | $404.9M | $458.3M | ||
| Q1 25 | $362.6M | $458.3M | ||
| Q4 24 | — | $503.1M | ||
| Q3 24 | $355.8M | $525.9M | ||
| Q2 24 | $355.8M | $546.0M | ||
| Q1 24 | $355.8M | $570.3M |
总资产FVRROFIX
| Q4 25 | — | $850.6M | ||
| Q3 25 | $1.1B | $832.6M | ||
| Q2 25 | $1.1B | $837.2M | ||
| Q1 25 | $1.1B | $823.1M | ||
| Q4 24 | — | $893.3M | ||
| Q3 24 | $1.0B | $867.9M | ||
| Q2 24 | $1.0B | $882.0M | ||
| Q1 24 | $1.0B | $906.0M |
负债/权益比FVRROFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $53.0M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $52.1M | $16.8M |
| 自由现金流率自由现金流/营收 | 18.1% | 7.6% |
| 资本支出强度资本支出/营收 | 0.3% | 4.9% |
| 现金转化率经营现金流/净利润 | 9.81× | — |
| 过去12个月自由现金流最近4个季度 | $124.9M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流FVRROFIX
| Q4 25 | — | $27.7M | ||
| Q3 25 | $53.0M | $12.4M | ||
| Q2 25 | $42.2M | $11.6M | ||
| Q1 25 | $21.2M | $-18.4M | ||
| Q4 24 | — | $23.7M | ||
| Q3 24 | $10.9M | $11.7M | ||
| Q2 24 | $32.2M | $9.0M | ||
| Q1 24 | $21.2M | $-18.6M |
自由现金流FVRROFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | $52.1M | $2.5M | ||
| Q2 25 | $41.5M | $4.5M | ||
| Q1 25 | $20.8M | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | $10.6M | $6.3M | ||
| Q2 24 | $31.5M | $-360.0K | ||
| Q1 24 | $20.8M | $-29.1M |
自由现金流率FVRROFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | 18.1% | 1.2% | ||
| Q2 25 | 22.0% | 2.2% | ||
| Q1 25 | 22.3% | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | 3.9% | 3.2% | ||
| Q2 24 | 17.8% | -0.2% | ||
| Q1 24 | 23.7% | -15.4% |
资本支出强度FVRROFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | 0.3% | 4.8% | ||
| Q2 25 | 0.4% | 3.5% | ||
| Q1 25 | 0.4% | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | 0.1% | 2.7% | ||
| Q2 24 | 0.4% | 4.7% | ||
| Q1 24 | 0.4% | 5.6% |
现金转化率FVRROFIX
| Q4 25 | — | — | ||
| Q3 25 | 9.81× | — | ||
| Q2 25 | 10.40× | — | ||
| Q1 25 | 26.90× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FVRR
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
